2022, ' Safety and efficacy of propranolol for treatment of familial cerebral cavernous malformations (Treat_CCM) : a randomised, open-label, blinded-endpoint, phase 2 pilot trial ', Lancet Neurology, vol. 22, no. 1, pp. 35-44 . https://doi.org/10.1016/S1474-4422(22)00409-4